Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.
about
Antifungal Th Immunity: Growing up in FamilyDiagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questionsIsavuconazole: A New Broad-Spectrum Triazole Antifungal AgentSystematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipientsTh17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis.Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis.Clinical and microbiological characteristics, and impact of therapeutic strategies on the outcomes of children with candidemia.Invasive fungal infections in transplant recipientsPrognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosisFactors associated with mortality in transplant patients with invasive aspergillosisCryptococcosis in patients with hematological diseases: a 14-year retrospective clinical analysis in a Chinese tertiary hospital.Invasive aspergillosis due to Neosartorya udagawaeThe utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections.Early Diagnosis of Invasive Aspergillosis in Neutropenic Patients. Comparison between Serum Galactomannan and Polymerase Chain Reaction.International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.Treatment options in Invasive Aspergillosis.Antifungal clinical trials and guidelines: what we know and do not knowSalvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis.Abdominal candidiasis is a hidden reservoir of echinocandin resistance.Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapyPopulation pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational studyClinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Voriconazole monitoring in children with invasive fungal infectionsEarlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definitionObservational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009Platelet parameters and (1, 3)-β-D-glucan as a diagnostic and prognostic marker of invasive fungal disease in preterm infants.Real-time nucleic acid sequence-based amplification to predict the clinical outcome of invasive aspergillosis.Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis.Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis.A Single Center Experience for Antifungal Prophylaxis in Patients with Acute Myelogenous Leukemia.Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patientsPulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.Clinical Features and Prognosis of Invasive Pulmonary Aspergillosis in Korean Children with Hematologic/Oncologic DiseasesInvasive Fusariosis in the Voriconazole Era: Single-Center 13-Year ExperienceBaseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis.Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.
P2860
Q27002920-A18ADE7F-D8FB-436A-9D3B-05FFA03CC9CDQ27015890-3B31E762-56E4-4E58-AB5C-FA2DF63F3D41Q28082019-8014A85F-6B8E-498E-8B81-CC94637B7D6AQ28083874-2B509387-303C-4888-8BA8-C6874ACA5B9AQ30415829-99D72D6E-863B-4C48-8206-959052E368DEQ30608976-3EFE3129-5887-41E2-BF22-AF979D5BD3B1Q33678622-49B3F7AE-8733-4B4C-BD91-F4B388ACBB87Q33683476-ABD6DB46-AAD8-42BF-9F9F-85B19A9365D0Q33695215-35CD5B44-F52D-4C1C-B371-67DC518743B3Q33769712-B2E7612A-DB1E-4CB7-941B-26E2FB0E0476Q33867013-C9BF90F3-5A72-4873-B450-C1D67B6A4DE3Q33868567-43DD366F-06B2-4D08-A3A0-434280226697Q33909352-B45C3589-F05F-4B29-8A37-647C35A35225Q34022755-8D22CFCD-F553-4C62-A77D-8FD5F8B47F73Q34052696-59164439-DDD9-4C92-8D5B-F2DA8E7877A6Q34151084-6FA7FA9D-8AB5-4750-9AD6-008AFC58C311Q34357504-CBE4A542-748B-46C6-BACB-44F3BA4A358CQ34400255-07C4E1DA-40F9-4B55-AD79-8EF4C7F2295DQ34543970-B44E8575-F9E2-45B6-AA06-D81BF4A813C1Q34597421-6EE4BDE9-4B5C-4A23-8789-46BEEA353664Q34737174-922E921B-0380-4A45-AAC0-B9E208E47CA2Q34932330-A0C34BC2-0EF0-4372-91D5-1667EA25548EQ34978993-9B421B55-A1E1-435C-9167-2504F47A5416Q35086478-2D32547F-EB12-4C56-B2C7-9059B8951F33Q35157940-0498B493-244E-4FFF-8408-AAEE52C63C79Q35194409-97E520D2-BDDD-42CC-A03E-7598215858EEQ35270270-EC2DA9F6-C278-4A53-A1B3-D985AA7D7714Q35364288-8911867C-72D1-46FE-BC30-170688FDE330Q35394057-C6376834-D46C-44B3-B0BC-0A4EF61D000FQ35638993-AB053BB8-A255-421D-86F5-DD9880489117Q35672970-61F53D5F-750D-47A6-8CEE-20151EB4D368Q35689788-037A1FD7-FA2F-4437-B398-F57F49387708Q35736934-0FC9C3E0-06E8-48FB-BF32-0A31E84D1050Q35756513-6E3409BB-BCDF-4A5F-A5DE-BA77CFE1F7CCQ35807013-0684FAAA-44A2-4538-B3B5-5AE1DD89DA66Q35889014-8A1ABDE9-EFB0-4983-AF44-96C249A02136Q35905124-FB27B176-D5CD-405D-9429-BEB64BC0A427Q35916585-A6178350-8434-42E4-9D63-34038540BF48Q36115615-57BE40CD-9704-4F13-B565-728DDF844237Q36171611-C35917D8-FC7F-4912-81FE-37E8C42154CB
P2860
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Defining responses to therapy ...... of Cancer consensus criteria.
@en
Defining responses to therapy ...... of Cancer consensus criteria.
@nl
type
label
Defining responses to therapy ...... of Cancer consensus criteria.
@en
Defining responses to therapy ...... of Cancer consensus criteria.
@nl
prefLabel
Defining responses to therapy ...... of Cancer consensus criteria.
@en
Defining responses to therapy ...... of Cancer consensus criteria.
@nl
P2093
P2860
P50
P356
P1476
Defining responses to therapy ...... of Cancer consensus criteria.
@en
P2093
Bart-Jan Kullberg
Ben E De Pauw
Bertrand Dupont
Brahm H Segal
Carol A Kauffman
Catherine Cordonnier
Claudio Viscoli
David A Stevens
Dimitrios P Kontoyiannis
Eric J Bow
P2860
P304
P356
10.1086/590566
P407
P577
2008-09-01T00:00:00Z